Weight Loss Drugs Linked to Rare Brain Disorder

A rare but serious neurological disorder, Wernicke encephalopathy, has been identified in individuals taking GLP-1 receptor agonist medications, including those used for weight loss. Researchers noted 15 reported cases linked to drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).

These cases, documented through FDA reports and medical literature, often coincided with gastrointestinal issues like nausea, vomiting, and appetite loss. Such symptoms can contribute to severe vitamin B1 deficiency, a critical factor in brain function. Untreated, this deficiency can result in confusion, balance problems, and potentially permanent neurological damage or death.

While the medications' direct causation is not proven, experts suggest that reduced appetite and gastrointestinal side effects from GLP-1 drugs may increase the risk of B1 deficiency. Individuals with persistent vomiting, rapid weight loss, or a history of bariatric surgery may be at higher risk.

Medical professionals advise patients not to discontinue their prescribed GLP-1 medications but to remain vigilant. Persistent or severe symptoms, such as prolonged vomiting or diarrhea, warrant immediate medical consultation to rule out serious complications and ensure adequate nutrient intake.